By Charles Bankhead, Staff Writer, MedPage Today
Published: August 12, 2010
Reviewed by Zalman S. Agus, MD; Emeritus Professor
University of Pennsylvania School of Medicine and
Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner
Regardless of whether they were treated with standard or reduced-intensity chemotherapy, followed by radiation, patients with early-stage Hodgkin's lymphoma had similar rates of disease control, results of a large European study showed....
FOLFOX4 Extends Survival in Patients With Metastatic Hepatocellular Carcinoma: Presented at ESMO-GI
By Chris Berrie
BARCELONA, Spain -- July 2, 2010 -- The FOLFOX4 regimen is well tolerated and provides greater survival and response benefits than doxorubicin in Asian patients with hepatocellular carcinoma (HCC), specifically those with metastatic disease. The findings, based on a subanalysis of the EACH study, were presented here at the European Society for Medical Oncology's...
Lymphoma patients with cardiovascular disease have increased risk of cardiac hospitalisation
Science Centric | 3 July 2010 08:51 GMT
Older patients with Hodgkin lymphoma (HL) and a history of heart disease face a high risk of hospitalisation for cardiac complications after completing treatment, according to research published online today in Blood, the journal of the American Society of Hematology. HL is a form of cancer of arising in the lymph nodes, and approximately...
SAN DIEGO--(BUSINESS WIRE)--NexMed, Inc. (Nasdaq: NEXMD), a specialty CRO with a pipeline of product candidates based on the NexACT® technology, today announced that the Company will present data at the International Liver Cancer Association (ILCA) Fourth Annual Conference from September 10-12, 2010 in Montreal, Canada. The presentation, entitled, “PrevOnco® Exhibits In Vitro Cytolytic...
Leiden, June 14 2010 to-BBB, the Dutch brain drug delivery company, has received a positive opinion from the Committee for Orphan Medicinal Products (COMP) on the orphan medicinal product designation for the company’s brain cancer lead candidate 2B3-101.
As a proprietary brain-targeted version of the marketed product Caelyx®/Doxil® (PEG-liposomal doxorubicin), 2B3-101 uses glutathione (GSH) to safely enhance the delivery of doxorubicin across the blood-brain...
